DOCSLIB.ORG

Pharma Patents Granted During 2010-11 to 2013-14 ( Up

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharma Patents Granted During 2010-11 to 2013-14 ( Up PHARMA PATENTS GRANTED DURING 2010-11 TO 2013-14 ( UP TO 31-7-2013) Application No Date of Filing Patent No Patent Grant Date Title Applicant 1074/MUM/2006 07-07-2006 239822 01-04-2010 A MODIFIED RELEASE PHARMACEUTICAL COMPOSITION PANACEA BIOTEC LIMITED OF BICALUTAMIDE 1115/MUMNP/2007 25-07-2007 238424 02-04-2010 A TRIAZOLO [4,5-d]PYRIMIDINE COMPOUND OF ASTRA ZENECA AB FORMULA (II) 3902/DELNP/2005 01-09-2005 239827 05-04-2010 A GEL FORMULATIONS ANTARES PHARMA IPL AG 359/CAL/1995 31-03-1995 239838 06-04-2010 A 1 H-SUBSTITUTED-INDOLE-3-GLYOXYLAMIDE ELI LILLY AND COMPANY COMPOUND AND PROCESS OF PREPARATION THEREOF 13/CAL/2000 10-01-2000 239851 06-04-2010 NOVEL BENZOTHIOPHENE COMPOUNDS, ELI LILLY AND COMPANY INTERMEDIATES, COMPOSITIONS AND METHODS THEREOF 3803/DELNP/2005 26-08-2005 239895 07-04-2010 A PHARMACEUTICAL COMPOSITION FOR TREATING OR JARROW FORMULAS, INC. PREVENTING HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION, MALARIA OR BOTH 3702/DELNP/2006 28-06-2006 239909 09-04-2010 FURANCARBONYLGUANIDINE DERIVATIVES, THEIR KOREA RESEARCH INSTITUTE OF PREPARATION AND PHARMACEUTICAL COMPOSITIONS CHEMICAL TECHNOLOGY. CONTAINING THEM 1165/DELNP/2005 23-03-2005 239936 12-04-2010 A PHARMACEUTICAL FORMULATION FOR TREATMENT SHIRE LLC OF PATIENTS HAVING ATTENTION DEFICIT HYPERACTIVITY DISORDER(ADHD) 2221/DELNP/2006 24-04-2006 239954 15-04-2010 NUTRITIONAL COMPOSITION AGAINST SIDE EFECTS OF NESTEC S.A. CHEMOTHERAPY OR RADIOTHERAPY 1053/DELNP/2004 20-04-2004 239997 21-04-2010 A LYOPHILIZED PHARMACEUTICAL COMPOSITION PFIZER PRODUCTS INC. 5037/DELNP/2005 03-11-2005 240018 23-04-2010 SUBSTITUTED-1-PHTHALAZINAMES AS VR-1 MERCK SHARP & DOHME LIMITED ANTAGONISTS 2695/DEL/2005 07-10-2005 240034 23-04-2010 A PROCESS TO OBTAIN A PHARMACEUTICAL PRODUCT MADAN, DR. ANIL KUMAR WITH AN ENHANCED DISSOLUTION RATE AND THE PHARMACEUTICAL PRODUCT RESULTING THEREOF IN/PCT/2002/01295/DEL 27-12-2002 240070 27-04-2010 A PHARMACEUTICAL COMPOSITION FOR INTRANASAL ASUBIO PHARMA CO., LTD ADMINSTRATION COMPRISING A HUMAN PARATHYROID HORMONE PEPTIDE OR ITS DERIVATIVE" 877/MUMNP/2007 11-06-2007 240123 28-04-2010 AN OILY ISOTROPE PHARMACEUTICAL COMPOSITION SA VETOQUINOL 402/DELNP/2006 23-01-2006 240207 29-04-2010 A FLUORO SUBSTITUTED OMEGA-CARBOXYARYL BAYER HEALTHCARE LLC DIPHENYL UREA COMPOUND OR A SALT, AN ISOLATED STEREOISOMER THEREOF 365/DELNP/2005 01-02-2005 240219 29-04-2010 A COMPOUND 2-(3-AMINOARYL) AMINO-4-ARYL- AB SCIENCE THIAZOLES OF FORMULA I. 50/CAL/2001 30-01-2001 240197 29-04-2010 A VACCINE PREPARED FOR THE TREATMENT OR RICAN LIMITED PROPHYLAXIS OF HELICOBACTER PYLORI INFECTION 3435/DELNP/2004 04-11-2004 240229 30-04-2010 A 3, 17-DISUBSTITUTED MORPHINAN COMPOUND AND JENKEN BIOSCIENCES, INC PHARMACEUTICAL COMPOSITION THEREOF 1599/DELNP/2005 20-04-2005 240249 30-04-2010 AN IMIDAZOLE COMPOUND USES AS CARDIOVASCULAR PORTELA & C.A., SA. AGENTS 1516/DELNP/2005 15-04-2005 240264 30-04-2010 AN ANALOGUE OF KAHALALIDE F PHARMA MAR, S.A.U 4540/DELNP/2006 07-08-2006 240268 30-04-2010 NEW AZABICYCLIC COMPOUNDS, A PROCESS FOR THEIR LES LABORATORIES SERVIER PREPARATION AND PHARMACEUTICAL. COMPOSITIONS CONTAINING THEM 927/KOLNP/2006 13-04-2006 240314 04-05-2010 DERIVATIVES OF N-[PHENYL (PYRROLIDINE-2-YL) SANOFI-AVENTIS METHYL ] BENZAMIDE AND N-[ ( AZEPAN-2-YL ) PHENYLMETHYL ] BENZAMIDE, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS IN/PCT/2002/01272/DEL 20-12-2002 240340 05-05-2010 A COMPOSITION USEFUL AGAINST NEURONAL DAMAGE HUNTER FLEMING LIMITED 30/DELNP/2003 10-01-2003 240341 05-05-2010 A PYRIDOPYRROLOPYRIMIDINE COMPOUND USED AS PHARMA MAR, S.A. ANTITUMOURAL AGENT 1286/DELNP/2005 31-03-2005 240358 05-05-2010 DEVELOPMENT OF NOVEL HEREBAL FORMULATION COUNCIL OF SCIENTIFIC & INDUSTRIAL USED AS AN ANTI-DIABETIC ON TRADITIONAL RESEARCH INDIGENOUS KNOWLEDGE IN/PCT/2001/01142/MUM 19-09-2001 240371 06-05-2010 ANTHELMINTIC COMPOSITIONS ASHMONT HOLDINGS LIMITED 6170/DELNP/2005 30-12-2005 240378 06-05-2010 HYDROXYPYRIDINE CGRP RECEPTOR ANTAGONISTS MERCK AND CO.INC. 4733/DELNP/2005 18-10-2005 240379 06-05-2010 PHARMACEUTICAL FORMULATION OF THE SODIUM BOEHRINGER INGELHEIM SALT OF TELMISARTAN INTERNATIONAL GMBH IN/PCT/2001/00708/DEL 08-08-2001 240383 06-05-2010 A BRANCHED CHAIN AMINO ACID-DEPENDENT WARNER-LAMBERT COMPANY AMINOTRANSFERASE INHIBITORS COMPOUND 779/MUMNP/2006 05-07-2006 240396 07-05-2010 A PHARMACEUTICAL COMPOSITION CONTAINING MERZ PHARMA GMBH & CO. KGAA MEMANTINE FOR THE TREATMENT OF MILD AND MILD- TO-MODERATE ALZHEIMER S DISEASE 1330/DEL/2004 19-07-2004 240422 10-05-2010 A HERBAL COMPOSITION FOR THE TREATMENT OF HIV PANDEY , SANTOSH KUMAR AND A PROCESS OF PREPARING THE SAME 446/KOLNP/2004 02-04-2004 240474 12-05-2010 PHARMACEUTICAL COMPOSITION COMPRISING GAMA- KALVINSH IVARS BUTYROBETAINE 5950/DELNP/2005 20-12-2005 240515 14-05-2010 HETEROARYLOXY NITROGENOUS SATURATED BANYU PHARMACEUTICAL CO.,LTD. HETEROCYCLIC DERIVATIVE 767/DELNP/2006 15-02-2006 240599 19-05-2010 , SPRAY-DRIED AMORPHOUS POWDER BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG. 1903/DELNP/2004 02-07-2004 240690 26-05-2010 COMPOSITION, SYNTHESIS, DIAGNOSTIC AND MICHAEL A. MURPHY  THERAPEUTIC APPLICATIONS OF POLYAMINES 1564/DELNP/2005 19-04-2005 240734 26-05-2010 AN IMMUNOGEN FOR PREPARATION OF THERAPEUTIC INSTITUTE OF IMMUNOLOGY, PLA VACCINES FOR TREATMENT OF HEPATITIS B AND PRODUCING METHOD THEREOF 2657/DELNP/2004 09-09-2004 240755 28-05-2010 PHARMACEUTICAL PREPARATION CONTAINING EURO-CELTIQUE S.A., OXYCODONE AND NALOXONE" 450/DELNP/2005 07-02-2005 240762 28-05-2010 A METALLOPROTEINASE INHIBITOR COMPOUND AND ASTRAZENEECA AB PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME 762/DEL/2000 25-08-2000 240763 28-05-2010 AN IMPROVED MALE CONTRACEPTIVE FORMULATION SUJOY KUMAR GUHA 714/MUMNP/2006 19-06-2006 240768 31-05-2010 COMPOSITION AND METHOD FOR REDUCING THE HINDUSTAN UNILEVER LIMITED EFFECTS OF STRESS ON SKIN CONDITION 946/KOLNP/2006 17-04-2006 240787 01-06-2010 DERIVATIVES OF N-[PHENYL(ALKYLPIPERIDINE-2- SANOFI-AVENTIS YL)METHYL]BENZAMIDE 1693/DELNP/2004 15-06-2004 240817 02-06-2010 ISOTRETINOIN NANOPARTICULATE COMPOSITIONS RANBAXY LABORATORIES LIMITED 5582/DELNP/2005 01-12-2005 240818 02-06-2010 A SUBSTITUTED BENZAMIDE COMPOUND AND ASTELLAS PHARMA INC. PHARMACEUTICAL COMPOSITION THEREOF 921/DEL/1998 13-04-1998 240834 03-06-2010 A CELL STRUCTURE MEDIUM COMPOSITION FOR THE BAYER CORPORATION PRODUCTION OF RECOMBINANT FACTOR VIII 4611/DELNP/2005 10-10-2005 240846 04-06-2010 SELECTIVE SPIROCYCLIC GLUCOCORTICOID RECEPTOR MERCK SHARP & DOHME CORP., MODULATORS 640/DELNP/2005 18-02-2005 240871 07-06-2010 COMPOSITION FOR SOLUBILIZATION OF PACLITAXEL DAEHWA PHARM. CO., LTD. AND PREPARATION METHOD THEREOF IN/PCT/2002/1483/KOL 02-12-2002 240925 10-06-2010 A TOPICAL ORAL COMPOSITION THE PROCTER & GAMBLE COMPANY 2210/CAL/1998 23-12-1998 240930 10-06-2010 PRODRUGS OF ASPARTYL PROTEASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED 1185/DEL/1999 07-09-1999 240939 10-06-2010 A SPATTER CURE COMPOUND AND A PROCESS FOR THE MADAN MOHAN BANDYOPADHYAY PREPARATION THEREOF FOR USE DURING THE WELDING PROCESS 925/KOLNP/2006 13-04-2006 240989 14-06-2010 N - HETEROCYCLYL - METHYLBENZAMIDE DERIVATIVE SANOFI-AVENTIS COMPOUNDS 3115/DELNP/2005 13-07-2005 240990 14-06-2010 A PHARMACEUTICAL COMPOSITION COMPRISING AN ASTRAZENECA AB AROMATASE INHIBITOR,A PROGESTIN AND AN OESTROGEN 461/DELNP/2005 07-02-2005 241002 14-06-2010 COMPOSITION COMPRISING THE EXTRACT OF Helixir Co., Ltd. ACTINIDIA ARGUTA AND RELATED SPECIES FOR THE PREVENTION AND TREATMENT OF ALLERGIC DISEASE AND NON-ALLERGIC INFLAMMATORY DISEASE 5320/DELNP/2005 21-11-2005 241017 15-06-2010 MACROCYCLIC QUINAZOLINE DERIVATIVES AS JANSSEN PHARMACEUTICA N.V. ANTIPROLIFERATIVES AGENTS 228/DELNP/2004 03-02-2004 241018 15-06-2010 NOVEL COMPOUNDS AS ANTI-INFLAMMATORY, 4SC AG Germany IMMUNOMODULATORY AND ANTI-PROLIFERATORY AGENTS 250/MUM/2004 01-03-2004 241016 15-06-2010 GASTRIC RETENTION CONTROLLED DRUG DELIVERY SUN PHARMA ADVANCED RESEARCH SYSTEM COMPANY LIMITED 1910/KOLNP/2004 13-12-2004 241066 17-06-2010 TRICYCLIC COMPOUNDS AS MODULATORS OF STEROID ELI LILLY AND COMPANY HORMONE NUCLEAR RECEPTORS 1077/MUMNP/2005 03-10-2005 241110 17-06-2010 POLYMERIC OLIGONUCLEOTIDE PRODRUGS ENZON PHARMACEUTICALS, INC. 207/CAL/1998 09-02-1998 241050 17-06-2010 PEPTIDES FOR DIAGNOSING AND TREATMENT OF GERHILD WILDNER AUTOIMMUNE DISEASES IN/PCT/2003/00001/DEL 01-01-2003 241117 18-06-2010 TOPICAL LIPOSOMAL FORMULATION COMPRISING CENTRO DE INVESTIGACIÓN Y CLOBETASOL PROPIONATE ENCAPSULATED IN DESARROLLO DE MEDICAMENTOS LIPOSOMES (CIDEM) 1210/DEL/2004 30-06-2004 241119 18-06-2010 A NOVEL COBALT COMPLEX USEFUL FOR REVERSAL OF INDIAN COUNCIL OF MEDICAL DRUG RESISTANCE AND THE PREPARATION THEREOF RESEARCH 1437/MUMNP/2006 27-11-2006 241166 22-06-2010 AN IMMEDIATE RELEASE DOSAGE FORMULATION MERZ PHARMA GMBH & CO. KGAA COMPRISING MEMANTINE OR NERAMEXANE 3593/DELNP/2004 17-11-2004 241169 22-06-2010 IMMUNE STIMULATING AND CONTROLLING EYEGENE INC., COMPOSITION COMPRISING BACTERIAL CHROMOSOMAL DNA FRAGMENTS AND NON-TOXIC LIPOPOLYSACCHARIDES 797/DELNP/2006 16-02-2006 241200 23-06-2010 A COMPOSITION FOR TREATMENT OF DIABETES AYURVEDIC-LIFE INTERNATIONAL, LLC. 3456/DELNP/2005 03-08-2005 241228 24-06-2010 A COMPOSITION MATERIAL FOR TRANSMUCOSAL MAGLE HOLDING AB DELIVERY IN/PCT/2002/00673/DEL 05-07-2002 241240 24-06-2010 BENZAMIDAZOLE DERIVATIVE TEIJIN LIMITED 2008/DEL/1998 14-07-1998 241229 24-06-2010 A TRIAOLO[4, 5-D] PYRIMIDINE COMPOUND OF ASTRAZENECA UK LIMITED, FORMULA (I) 3338/CHENP/2006 14-09-2006 241259 25-06-2010 A PHARMACEUTICAL FORMULATION FOR TREATMENT THE REGENTS OF THE UNIVERSITY OF OF AIRWAY MUCUS HYPERSECRETION CALIFORNIA 510/DELNP/2005 10-02-2005 241260 25-06-2010 PHARMACEUTICAL COMPOSITIONS FOR INHALATION BOEHRINGER INGELHEIM PHARMA CONTAINING A NEW ANTICHOLINERGIC IN GMBH & CO. KG. CONJUNCTION WITH CORTICOSTEROIDS AND BETAMIMETICS 2187/DELNP/2006 21-04-2006 241296 28-06-2010 A COMPOSITION USEFUL FOR TREATMENT OF A ALLERGAN  INC.
Load more

Recommended publications
  • St. John's Wort 2018
    ONLINE SERIES MONOGRAPHS The Scientific Foundation for Herbal Medicinal Products Hyperici herba St. John's Wort 2018 www.escop.com The Scientific Foundation for Herbal Medicinal Products HYPERICI HERBA St. John's Wort 2018 ESCOP Monographs were first published in loose-leaf form progressively from 1996 to 1999 as Fascicules 1-6, each of 10 monographs © ESCOP 1996, 1997, 1999 Second Edition, completely revised and expanded © ESCOP 2003 Second Edition, Supplement 2009 © ESCOP 2009 ONLINE SERIES ISBN 978-1-901964-61-5 Hyperici herba - St. John's Wort © ESCOP 2018 Published by the European Scientific Cooperative on Phytotherapy (ESCOP) Notaries House, Chapel Street, Exeter EX1 1EZ, United Kingdom www.escop.com All rights reserved Except for the purposes of private study, research, criticism or review no part of this text may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, without the written permission of the publisher. Important Note: Medical knowledge is ever-changing. As new research and clinical experience broaden our knowledge, changes in treatment may be required. In their efforts to provide information on the efficacy and safety of herbal drugs and herbal preparations, presented as a substantial overview together with summaries of relevant data, the authors of the material herein have consulted comprehensive sources believed to be reliable. However, in view of the possibility of human error by the authors or publisher of the work herein, or changes in medical knowledge, neither the authors nor the publisher, nor any other party involved in the preparation of this work, warrants that the information contained herein is in every respect accurate or complete, and they are not responsible for any errors or omissions or for results obtained by the use of such information.
    [Show full text]
  • Assessment Report on Hypericum Perforatum L., Herba
    European Medicines Agency Evaluation of Medicines for Human Use London, 12 November 2009 Doc. Ref.: EMA/HMPC/101303/2008 COMMITTEE ON HERBAL MEDICINAL PRODUCTS (HMPC) ASSESSMENT REPORT ON HYPERICUM PERFORATUM L., HERBA 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) 74 18 84 00 Fax (44-20) 75 23 70 51 E-mail: [email protected] http://www.emea.europa.eu © European Medicines Agency, 2009. Reproduction is authorised provided the source is acknowledged TABLE OF CONTENTS I. REGULATORY STATUS OVERVIEW...................................................................................4 II. ASSESSMENT REPORT............................................................................................................5 II.1 INTRODUCTION..........................................................................................................................6 II.1.1 Description of the herbal substance(s), herbal preparation(s) or combinations thereof 6 II.1.1.1 Herbal substance:........................................................................................................ 6 II.1.1.2 Herbal preparation(s): ................................................................................................ 7 II.1.1.3 Combinations of herbal substance(s) and/or herbal preparation(s)........................... 9 Not applicable. ................................................................................................................................9 II.1.1.4 Vitamin(s) ...................................................................................................................
    [Show full text]
  • Dr. Duke's Phytochemical and Ethnobotanical Databases List of Chemicals for Kidney Stones
    Dr.
    [Show full text]
  • 20 13 Rep Or T
    2013 REPORT More Than 240 Medicines in Development for Leukemia, Lymphoma and Other Blood Cancers Every 4 minutes a person is diagnosed with leukemia, Medicines in Development lymphoma or For Leading Blood Cancers myeloma; Accounting for Application Submitted 9% of all cancers Phase III diagnosed each year Phase II Biopharmaceutical research companies • 15 each for myeloproliferative neo- Phase I are developing 241 medicines for blood plasms, such as myelofibrosis, poly- cancers—leukemia, lymphoma and cythemia vera and essential throm- 97 98 myeloma. This report lists medicines in bocythemia; and for myelodysplastic human clinical trials or under review by syndromes, which are diseases affect- the U.S. Food and Drug Administration ing the blood and bone marrow. (FDA). These medicines in development offer The medicines in development include: hope for greater survival for the thou- sands of Americans who are affected by • 98 for lymphoma, including Hodgkin these cancers of the blood. and non-Hodgkin lymphoma, which 52 affect nearly 80,000 Americans each Definitions for the cancers listed in this year. report and other terms can be found on page 27. Links to sponsor company web • 97 for leukemia, including the four sites provide more information on the major types, which affect nearly potential products. 50,000 people in the United States 24 each year. For information on the value of medi- cines, an in-depth look at current in- • 52 for myeloma, a cancer of the novation and key medical breakthroughs plasma cells, which impacts more benefiting blood cancer patients, please than 22,000 people each year in the see Medicines in Development for Leu- United States.
    [Show full text]
  • (2) Patent Application Publication (10) Pub. No.: US 2009/0226500 A1 Avelar Et Al
    US 20090226500A1 (19) United States (2) Patent Application Publication (10) Pub. No.: US 2009/0226500 A1 Avelar et al. (43) Pub. Date: Sep. 10, 2009 (54) SUTURES AND ANTI-SCARRINGAGENTS Related U.S. Application Data (75) Inventors: Rui Avelar, Vancouver (CA); (60) Provisional application No. 60/763,945, filed on Jan. Arpita Maiti, Vancouver (CA); 31, 2006. Philip M. Toleikis, Vancouver (CA); Johanne Diane Cashman, Publication Classification Vancouver (CA); David M. (51) Int. Cl. Gravett, Mountain View, CA (US) A6.1 F 2/04 (2006.01) Correspondence Address: A61 K. 3 1/135 (2006.01) SEED INTELLECTUAL PROPERTY LAW A61R 31/553 (2006.01) GROUP PLLC A61 K 31/496 (2006.01) 701 FIFTHAVENUE, SUITE 5400 A61 K 31/4164 (2006.01) SEATTLE, WA 98104-7092 (US) A61R 31/395 (2006.01) A61 K 37/426 (2006.01) (73) Assignee: Angiotech Pharmaceuticals, Inc, (52) U.S. Cl. .................... 424/423: 514/649; 514/211.08; Vancouver (CA) 514/254.07: 514/399; 514/183; 514/370 (21) Appl. No.: 12/162,572 (57) ABSTRACT (22) PCT Filed: Jan. 31, 2007 Sutures are used in combination with anti-scarring agents to (86) PCT No.: PCT/US07/02714 inhibit fibrosis between the sutures and the host tissues into which the sutures are inserted. Compositions and methods are § 371 (c)(1), described for use in reducing excessive scarring, surgical (2), (4) Date: May 6, 2009 adhesion, and other disorders. Patent Application Publication Sep. 10, 2009 Sheet 1 of 29 US 2009/0226500 A1 Patent Application Publication Sep. 10, 2009 Sheet 2 of 29 US 2009/0226500 A1 ºs||eoL-AHLKquoqonpoudp-JNLWu018=ºolZ802-14Ke8 Patent Application Publication Sep.
    [Show full text]
  • Natural Products of Relevance in the Prevention and Supportive Treatment of Depression
    Psychiatr. Pol. 2015; 49(3): 435–453 PL ISSN 0033-2674 (PRINT), ISSN 2391-5854 (ONLINE) www.psychiatriapolska.pl DOI: http://dx.doi.org/10.12740/PP/29367 Natural products of relevance in the prevention and supportive treatment of depression Bożena Muszyńska1, Maciej Łojewski 1,Jacek Rojowski 2, Włodzimierz Opoka 2, Katarzyna Sułkowska-Ziaja1 1Chair and Department of Pharmaceutical Botany, Jagiellonian University Medical College Head: prof. dr hab. H. Ekiert 2Chair of Inorganic and Analytical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College Head: dr hab. W. Opoka, prof. of Jagiellonian University Summary The use of herbs or their parts: leaves, roots, rhizomes, flowers, seeds, natural strains, as well as extracts or isolated metabolites is becoming more and more popular. Natural remedies not only act prophylactically, but also help to alleviate symptoms of many diseases and enhance the overall functioning of the internal organs. Many raw materials of natural origin plays a role in treatment of health problems, and also in case of serious diseases such as depression. Depres- sion (affective disorder) now affects about 10% of the population, but in next few years due to the development of civilization and increasing pace of life, the probable number of people suffering from this disease can grow rapidly. Natural raw materials such as Bacopa monnieri, Crocus sativus, Eleutherococcus senticosus, Griffonia simplicifolia, Hypericum perforatum, Sceletium tortuosum, Piper methysticum, Rhodiola rosea, Aspalathus linearis, Camellia sinensis, Ficus carica, Lycium chinense, Cuminum cyminum, Panax Ginseng can effectively assist the prevention and treatment of depression. Daily diet may also have positive effect in prevention of this disease.
    [Show full text]
  • LC-MS and LC-PDA Analysis of Hypericum Empetrifolium and Hypericum Sinaicum Feras Q
    LC-MS and LC-PDA Analysis of Hypericum empetrifolium and Hypericum sinaicum Feras Q. Alalia,*, Khaled Tawahab, and Mohammad Gharaibehc a Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Al Isra Private University, P. O. Box 22, 33, Amman 11622, Jordan. E-mail: [email protected] b Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Jordan, Amman 11942, Jordan c Department of Natural Resources and Environment, Faculty of Agriculture, Jordan University of Science and Technology, P. O. Box 3030, Irbid 22110, Jordan * Author for correspondence and reprint requests Z. Naturforsch. 64 c, 476 – 482 (2009); received February 25/March 26, 2009 Within the framework of our continuous efforts to explore Hypericum species from Jor- dan, we report the analysis of the major active metabolites, naphthodianthrones and phloro- glucinols, in the methanolic extracts of two under-explored Hypericum species; H. empetri- folium Willd. and H. sinaicum Hochst. & Steud. ex Boiss., using LC-(+,–)-ESI-MS (TIC and SIM) and LC-UV/Vis spectroscopy. Based on their LC-UV/Vis profi les, retention times and (+,–)-ESI-MS (TIC and SIM) spectral data, hypericin, protohypericin and pseudohypericin were identifi ed in both of the investigated species. In addition adhyperfi rin was only de- tected in H. empetrifolium, while hyperforin and protopseudohypericin were only detected in H. sinaicum. This is the fi rst report documenting the presence of hypericin, protohypericin, pseudohypericin, protopseudohypericin, and hyperforin in H. sinaicum, and adhyperfi rin in H. empetrifolium. Key words: Hypericum, Naphthodianthrones, Phloroglucinols Introduction species of Hypericum can be identifi ed by: (i) op- posite simple entire exstipulate leaves contain- Hypericum is a genus of about 450 species ing translucent and often black or red glandular of herbs or shrubs belonging to the family Clu- secretions; (ii) fl owers with a 5-merous perianth siaceae, formerly Hypericaceae.
    [Show full text]
  • Novartis Venture Funds
    N O V A R T I S VENTURE FUnDS activityreport 2010 2 l activity report 2010 Contents 04 Introduction 06 Investment Philosophy and Focus 08 Highlights 12 Our Funds 16 Geographic Presence 18 Pipelines of Portfolio Companies 22 Medical Device and Diagnostics 24 Private Equity Portfolio 32 Board of Directors 36 Fund Management 38 Contact Information 3 l activity report 2010 mission statement Investing in innovative life science companies for patient benefit creating attractive returns for entrepreneurs and investors 4 l activity report 2010 introduction francis waldvogel Letter from the Chairman of the Medical sciences have indeed never been as cre- Novartis Venture Fund ative, diversified, and dynamic as today, emerging Ranking systems have become fashionable: from from a real melting pot where physics, material sci- air transport to the life style of cities, from health ences, chemistry, biology, genetics, informatics and care systems to universities, we can today estab- robotics converge. Miniaturization and nanoscale lish the list of the best places to be in or the most developments also move into the field. We believe dedicated services to be bestowed with. Corporate therefore that this is a time for great opportuni- Venture Funds are also part of this trend, and to our ties to develop novel diagnostic tools, therapeu- great satisfaction, the Novartis Venture Funds (NVF) tic agents and medical devices for unmet patients’ have been ranked among the top performers in the needs, and that a diversified, multidisciplinary team life science field. is a must to develop these opportunities. Ranking systems, however, have their method- ological limitations and intellectual shortcomings.
    [Show full text]
  • Prospectus for the Admission to Trading on the Regulated Market
    Prospectus for the admission to trading on the regulated market operated by Euronext Amsterdam N.V. of 2,451,766 new ordinary bearer shares with no par value vested with full dividend rights as of 1 January 2018 from a capital increase against cash contributions as resolved by the management board with the consent of the supervisory board on 9 April 2019, registered in the Commercial Register on 10 April 2019 – each with a notional par value of EUR 1.00 per share – Vivoryon Therapeutics AG Halle (Saale) International Securities Identification Number (ISIN): DE0007921835 Ticker Symbol: VVY 26 June 2019 This document constitutes a prospectus for the purposes of the admission to trading of 2,451,766 new shares (the “Admission Shares”) on the regulated market operated by Euronext Amsterdam N.V. (the “Prospectus”). This Prospectus has been prepared in the English language in accordance with the Commission Regulation (EC) No 809/2004 of 29 April 2004 (the “Prospectus Regulation”) and conforms to the requirements of the German Securities Prospectus Act (Wertpapierprospektgesetz). Vivoryon Therapeutics AG is an SME in terms of art. 2 para. 1 f) in the Prospectus Directive (Prospektrichtlinie, “Prospectus Directive”) (No 2003/71/EC) and the level of disclosure of the Prospectus is proportionate to that type of issuer (Annex XXV of the Prospectus Regulation). This Prospectus has been approved by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht) after a review for completeness of the Prospectus, including a review for coherence and comprehensibility of the presented information, according to Section 13 (1) of the German Securities Prospectus Act (Wertpapierprospektgesetz), and notified to the Netherlands Authority for the Financial Markets (Autoriteit Financiële Markten) in accordance with Section 18 (1) of the German Securities Prospectus Act (Wertpapierprospektgesetz) and the European passport mechanism set out in the Prospectus Directive.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0285919 A1 Alberte Et Al
    US 20090285919A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0285919 A1 Alberte et al. (43) Pub. Date: Nov. 19, 2009 (54) RCE BRAN EXTRACTS FOR filed on Sep. 30, 2008, provisional application No. NFLAMMATION AND METHODS OF USE 61/147,305, filed on Jan. 26, 2009. THEREOF Publication Classification (76) Inventors: Randall S. Alberte, Estero, FL (51) Int. Cl. (US); William P. Roschek, JR., A 6LX 36/899 (2006.01) Naples, FL (US) A2.3L I/28 (2006.01) Correspondence Address: A6IP 29/00 (2006.01) FOLEY HOAG, LLP A6IP 25/00 (2006.01) PATENT GROUP, WORLD TRADE CENTER A6IP35/00 (2006.01) WEST (52) U.S. Cl. ......................................... 424/750; 426/655 155 SEAPORT BLVD BOSTON, MA 02110 (US) (57) ABSTRACT The present invention relates in part to stabilized rice bran (21) Appl. No.: 12/467,835 extracts enriched in compounds that have inhibitory activity against certain anti-inflammatory therapeutic endpoints, such (22) Filed: May 18, 2009 as the COX-1, COX-2 and 5-LOX enzymes. Another aspect of the invention relates to pharmaceutical compositions com Related U.S. Application Data prising the extracts and to methods of treating inflammatory (60) Provisional application No. 61/054,151, filed on May diseases comprising administering the aforementioned 18, 2008, provisional application No. 61/101.475, eXtractS. Patent Application Publication Nov. 19, 2009 Sheet 1 of 6 US 2009/0285919 A1 Figure l Arachidonic Acid NSAIDs inhibition Prostaglandins PRO-NFLAMMATORY Arthritis (OA & RA) Patent Application Publication Nov. 19, 2009 Sheet 2 of 6 US 2009/0285919 A1 S.---------------Sssssssssss &s asy xxx s -Yvxxxxxxxxxxxxxxxxxxxx xxxx-xxxxxxxxxx:x O SSSSS i Patent Application Publication Nov.
    [Show full text]
  • An Updated List of Neuromedicinal Plants of Pakistan, Their Uses, and Phytochemistry
    Hindawi Evidence-Based Complementary and Alternative Medicine Volume 2019, Article ID 6191505, 27 pages https://doi.org/10.1155/2019/6191505 Review Article An Updated List of Neuromedicinal Plants of Pakistan, Their Uses, and Phytochemistry Abdul Waheed Khan ,1 Arif-ullah Khan ,2 Syed Muhammad Mukarram Shah,3 Aziz Ullah,4 Muhammad Faheem ,2 and Muhammad Saleem2 1 Department of Pharmacy, University of Lahore, Islamabad, Pakistan 2Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan 3Department of Pharmacy, University of Swabi, Khyber Pakhtunkhwa, Pakistan 4Department of Pharmacy, Forman Christian College, Lahore, Pakistan Correspondence should be addressed to Arif-ullah Khan; [email protected] Received 12 November 2018; Revised 14 January 2019; Accepted 5 February 2019; Published 3 March 2019 Guest Editor: Jos´e C. T. Carvalho Copyright © 2019 Abdul Waheed Khan et al. Tis is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Background. Almost every region of Pakistan is stacked with a large number of medicinal plants. Due to high cost and unavailability of allopathic medicines for the neurological diseases, especially in rural areas, traditional healers prescribe phytotherapy for various neurological diseases like epilepsy, depression, anxiety, insomnia, Alzheimer, and migraine. Such treatments are considered to be most efective by the native people. Methods. Te data was collected from articles published on medicinal plants of various districts of Pakistan, using article search engines like Medline, Pubmed, Web of Science, Science Direct, and Google Scholar. Also, information regarding various neurological uses and mode of applications of medicinal plants was obtained from traditional healers, folk medicine users, and local elderly people having knowledge of medicinal plants.
    [Show full text]
  • Antidepressant Activity of Hyperforin Conjugates of the St.John's Wort, Hypericum Perforatum Linn.: an Experimental Study
    Indian Journal of Experimental Biology VoL 39, December 2001, pp. 1302-1304 Antidepressant activity of hyperforin conjugates of the St.John's wort, Hypericum perforatum Linn.: An experimental study A V Muruganandam & S K Bhattacharya* Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221 005, India and S Ghosal Drug Research and Deve lopment Centre, 1078, Jessore Road, Calcutta 700 028, India Received 11 November 2000; revised 26 July 2001 Nine extracts of H. petforatwn, containing hyperfo rin in conjugated forms, but devoid of free hyperforin and adhyper­ forin, were subj ected to antidepressant screening using the forced swim test (FST). The observed activity was compared with that of SJW extracts containing hyperforin and adhyperforin (in free form). Results indicate that hyperforin conjugates exhibit significant antidepressant acti vity as evidenced by the reduced immobility period in the FST in rats. Extracts of Hypericum perforatum Linn. (St.John's ministered (50 mg/kg/day) orally for three days in wort, SJW) have shown significant antidepressant 0 .3% CMC suspension. The experiment was per­ activity in both expenmenta. 1 1· 2 an d c l'mtca . l stu d'te s 3 . formed after 45 min of the final administration of the Earli er, hypericin, a napthodiantherene derivative pre­ drugs or the vehicle. sent in SJW, was thought to be the active constituent SJW Extracts- In a typical experiment, the dried responsible for the antidepressant activit/. However, overground parts of the H. peiforatum (SJW), col­ in later studies the earlier results could not be con­ lected from Northern India, were extracted continu­ firmed5.
    [Show full text]